Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290069 | 0.89 | CYP3A4 (0.52) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL6292889 | 0.81 | CHRM2 (0.45) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL6292887 | 0.77 | CYP3A4 (0.53) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL7207224 | 0.77 | TDP1 (0.69) | CYP3A4CA1CA2TDP1CA12 | |
| Hydrochloric Acid SCHEMBL6289114 | 0.77 | CYP3A4 (0.43) | CYP3A4CA1CA2CA12CA9 | |
| SCHEMBL5415076 | 0.75 | CA1 (0.52) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL14102774 | 0.75 | CYP3A4 (0.75) | CYP3A4CA1CA2TDP1MAPT | |
| SCHEMBL6290071 | 0.75 | CYP3A4 (0.56) | CYP3A4CA1CA2TDP1MAPT | |
| SCHEMBL500235 | 0.75 | TDP1 (0.57) | CYP3A4CA1CA2TDP1CA12 | |
| SCHEMBL4889499 | 0.74 | CA1 (0.65) | CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0915832-B1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX INC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0915832-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5877297-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5872224-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5837878-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5777148-A | Boronic compound complexing reagents and highly stable complexes | PROLINX, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | CYP3A4 853/4885CA1 470/4885CA2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.